Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300755 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
A Phase 3 study of Gastroesophageal Reflux, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00300755: Completed Phase 3 study of Gastroesophageal Reflux, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00300755 is a Phase 3 study of Gastroesophageal Reflux that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 60 participants, below the 2,884-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300755, a Phase 3 study of Gastroesophageal Reflux, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
Primary Outcome
WGSS is the sum of 5 selected individual weekly GERD mean frequency scores: vomiting/regurgitation, choking/gagging, refusal to eat, difficulty swallowing and abdominal/belly pain. Symptoms were assessed using a parent-administered questionnaire. The score for each individual symptom ranged from 0 (no symptoms) to 3 (highest frequency of symptoms), giving a WGSS range of 0-15. Change = score at week of assessment minus baseline score. Final week was defined as the last 7 days of symptom scores c
Conditions Studied
Interventions
- DRUG pantoprazole sodium enteric-coated spheroid
Study Locations (20)
Florida
- - Gainesville
- - Jacksonville
- - Miami
- - Orlando
- - Pensacola
California
- - Oakland
- - Orange
- - Sacramento
- - San Diego
Kentucky
- - Lexington
- - Louisville
Massachusetts
- - Boston
- - Boston
Michigan
- - Flint
- - Southfield
Alabama
- - Mobile
Arizona
- - Phoenix
Delaware
- - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT00300755 record still lists
NCT00300755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,884-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which pantoprazole sodium enteric-coated spheroid is the first listed.
NCT00300755 names 20 study sites across 10 states, led by Florida, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00300755 about?
NCT00300755 is a clinical study titled "Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)". To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
What is the current status of trial NCT00300755?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2006-05. Estimated completion is 2008-04.
What conditions does trial NCT00300755 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux.
What interventions are being tested in trial NCT00300755?
The interventions under investigation include: pantoprazole sodium enteric-coated spheroid (DRUG).
Who is sponsoring clinical trial NCT00300755?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00300755 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00300755's enrollment target sits among peer trials
60 20th of 33 higher than 13 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
COMPLETED · Phase 3
-
Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD
COMPLETED · Phase 3
-
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
COMPLETED · Phase 3
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia